There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics (HRTX – Research Report) and Hanger Orthopedic (HNGR – Research Report) with bullish sentiments.
Heron Therapeutics (HRTX)
Jefferies analyst Biren Amin maintained a Buy rating on Heron Therapeutics on August 5 and set a price target of $25.00. The company’s shares closed last Friday at $15.31.
According to TipRanks.com, Amin is a 5-star analyst with an average return of 10.4% and a 48.4% success rate. Amin covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Forma Therapeutics Holdings, and Zentalis Pharmaceuticals.
Currently, the analyst consensus on Heron Therapeutics is a Strong Buy with an average price target of $31.33, representing a 101.9% upside. In a report issued on July 24, Needham also maintained a Buy rating on the stock with a $28.00 price target.
Hanger Orthopedic (HNGR)
In a report issued on August 6, Brian Tanquilut from Jefferies maintained a Buy rating on Hanger Orthopedic, with a price target of $22.00. The company’s shares closed last Friday at $20.60.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 4.1% and a 55.3% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as US Physical Therapy, Quest Diagnostics, and Encompass Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hanger Orthopedic with a $22.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.